TDR Examines Federal Incentives for Botanical Cannabis Medicines

The Dales Report reviewed the proposed 12-year exclusivity period for FDA-approved botanical drugs and its potential to draw investment into cannabinoid medicines. The video notes that the bill remains early in the House process, but Oklahoma operators should monitor whether federal incentives accelerate a parallel pharmaceutical cannabis market.